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Replication-dependent H3.1 and H3.2 histones are encoded by 11 genes. The H3 mRNA levels in brain astrocytomas using real-time RT-
PCR assay was examined. The sequence of primers and probe used in amplification was designed basing on the reference sequence GenBank
accession no. Z83737. The H3 mRNA levels correlated with tumor grade (R=0.56, P=0.0012), Ki-67 proliferative antigen labeling index
(R=0.58, P=0.0008) and patient survival time (R=0.50, P=0.005), discriminating low-grade and high-grade tumors. Quantification of H3
mRNA with real-time RT-PCR using the proposed pair of primers may supplement classic proliferative tests and predictive factors in brain
astrocytomas.
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1. Introduction H3/c, H3/d, H3/f, H3/h, H3/i, H3/j, H3/k, H3/l, and H3.2Proliferative potential of cancer cells, measured with
mitotic index, immunocytochemistry for Ki-67 and PCNA
antigens or flow cytometry for DNA content supplements
histological diagnosis and has an impact on therapeutic
decisions [2–4]. During the last decade, in situ hybridiza-
tion (ISH) for histone mRNA has been added to the battery
of proliferative tests [2,5,6]. The specificity of this technique
is warranted by the tight coupling of histone synthesis to the
replication of DNA during the S-phase of the cell cycle [7].
Expression of histone mRNA can also be assessed quanti-
tatively in surgical specimens and tissue cultures with
quantitative reverse transcriptase PCR (QRT-PCR) [8–11].
In ISH study of histone mRNA, probes detecting histone
H3 mRNA are usually used [6]. However, details regarding
specific isoform of labeled H3 mRNA are not provided in
relevant papers.
Histone H3 is encoded by non-allelic genes [1,12],
differing in coding sequence (cds), which reflects the
degenerate nature of the genetic code.
At the protein level, there are two subtypes of replica-
tion-dependent H3: H3.1, encoded by isoforms H3/a, H3/b,0925-4439/$ - see front matter D 2004 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbadis.2004.01.006
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E-mail address: twilczok@slam.katowice.pl (T. Wilczok).encoded by H3/m. These intronless genes, clustered on the
short arm of chromosome 6 (excluding H3/m located on
chromosome 1) contain a stem-loop structure instead of
poly(A) tail [1,12–14].
We decided to test a value of H3 mRNA quantitation in
assessing proliferative activity in brain astrocytomas. The
strategies addressing the problem of quantification of H3
mRNA are discussed.2. Materials and methods
2.1. Samples and patients
Thirty human brain astrocytoma specimens (grade II—
8 cases, grade III—12 and grade IV—10 cases) obtained
from adult patients (aged 28–69 years, mean: 49.8 years)
were studied. Informed consent was obtained from all the
patients before surgery. The study was approved by the
Bioethics Committee of the Medical University of Silesia,
Poland. The tumor grade was assessed according to WHO
classification [15]. Tumor tissue was immediately frozen in
liquid nitrogen and stored at 80 jC until RNA extraction.
For immunohistochemistry, the samples were fixed in 4%
neutral buffered formalin for 24 h and embedded in
paraffin.
Fig. 1. RT-PCR product on a 6% polyacrylamide gel after electrophoresis
and silver staining. H3j amplimer (200 bp) is visualized.
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The sequence of 11 replication-dependent histone H3
genes was compared with CLUSTALW Multiple Sequence
Alignment http://www.bio.lundberg.gu.se/edu/msf2.html.
2.3. QRT-PCR (TaqMan assay)
The primers and probes for amplification of arbitrarily
selected H3j mRNA (GenBank accession no. Z83737 [1])
were designed using Primer Expressk 1.0, ABI PRISM
(Applied Biosystems, USA). The sequences of primer
forward, reverse and probe were as follows:
PH3f 5VTGCCATTTCAGCGCCTGGTG 3V(197–217),
PH3r 5VCACGGATACGACGCGCAAGC3V(377–397),
SH3 5VFAM-ACCTTCGTTTCCAGAGCTCGGCGGT-
3VTAMRA (245–270).
The expected size of the amplimer was 200 bp.
The total RNA in astrocytoma specimens was extracted
with acid guanidinium thiocyanate-phenol-chloroform tech-
nique [16]. The RNA extract was digested with DNase to
eliminate DNA. The standard curve was constructed afterTable 1
The degree of homology (%) in sequences of nucleotides of genes coding for histo
designed primers and probe
Gene Primer forward PH3f (%) Fluorogenic hybridization probe S
H3/j TGCCATTTCAGCGCCTGGTG 100 ACCTTCGTTTCCAGAGCTCGG
H3/a . A . . T . .C . . . . . . . .A . . . 80 . C . . . . . T . . . . . . . . . . .C .
H3/b . . . .A . . C. . . . .T . .A . . C 80 . T . . . . . T . . T . . . . . . . .G .
H3/c . . . .G . .C. . . . . . . . . . . . 80 . C . . . . . T . . . . . . . . . . .T .
H3/d . . . .G . .T . . . . . . . . . . . . 95 . C . . . . . C . . . . . . . . T . .C .
H3/f . A . .T . .T . . . . . . T . . . . A 80 . T . . . . . C . . . . . . . . . . .G .
H3/h . . . .T . .C. . A . . . . . . . . . 85 . T . . . . . C . . T . . . . . T . .C .
H3/i . A . .A . .C. . . . . T . . . . . A 80 . C . . . . . C . . . . . . . . . . .G .
H3/k . . . .T . .T . . . . . T . . . . . . 90 . CT . . . . C . . . . . . . . . . .C .
H3/l . . . .G. .C. . . . . . . . . . . . 90 . T . .T . . C . . . . . . . . . . .T .
H3/m . . . .G. .C. . . . . .T . . . . . 85 . T . .T . . A . . . . . . . . . . .G .amplification of five concentrations of h-actin mRNA using
h-actin Control Reagent kit (Applied Biosystems).
The PCR reaction was performed with the use of ABI
PRISM 7700 Sequence Detector (Applied Biosystems). The
reaction mixture at the final volume of 50 Al consisted of:
300 nM of each primer, 200 nM fluoregenic hybridization
probe, 2.5 units Tth DNA Polymerase (Epicentre), 200 AM
each of dATP, dTTP, dGTP, dCTP, 3 mM MgCl2, 0.75 mM
MnSO4, 1 TaqMan buffer A.
Cycling conditions were as follows: one step at 60 jC for
30 min, one step at 95 jC for 10 min, 45 cycles at 95 jC for
15 s and 60 jC for 1 min and one step at 72 jC for 10 min.
QRT-PCR assay was performed in duplicate for each
sample. The hybridization probe is labeled with a reporter
fluorescent dye (FAM) at the 5V end and a quencher-
fluorescent dye (TAMRA) at the 3Vend. When this probe
is placed in the PCR, the DNA polymerase that catalyzes the
PCR also cuts off any probe that specifically binds to
template. The nucleolytic degradation of the hybridization
probe releases the quenching of FAM fluorescence emis-
sion, resulting in an increase in peak fluorescence emission.
The higher the starting copy number of the mRNA target,
the earlier a significant increase in fluorescence is observed.
The principle of TaqMan assay has been described in detail
elsewhere [17].
PCR products were separated on a 6% polyacrylamide
gel, stained with silver and analyzed using Biotec-Fisher gel
documentation system and BASYS 1D software (Fig. 1).
The specificity of PCR reaction was further confirmed by
sequencing with ABI PRISM 377 sequencer (Applied Bio-
systems) (Fig. 2). The results of QRT-PCR were expressed
as the H3 mRNA copy number per microgram of total RNA.
2.4. Immunohistochemistry for Ki-67 protein
Paraffin 5-Am-thick tissue sections were examined. An-
tigen retrieval was performed by boiling sections in citrate
buffer (pH 6.0, 25 min). The monoclonal antibody Ki-S5
(DAKO, Denmark) diluted at 1:25 was used. Antibodynes H3 mRNA, as compared in the regions complementary to sequences of
H3 (%) Primer reverse PH3r (%) GenBank
accession
no.
Reference
CGGT 100 GCTTGCGCGTCGTATCCGTG 100 Z83737 [1]
. T . . 88 . . .C . . C . . . . . . . . C . .C . 75 Z46261 [18]
. . . . 88 . . . T . . T . . . . . . . . T . . T . 80 Z80784 [18]
. . . . 92 . . .G. . A . . T . . . . .C . . T . 85 X57128 [19]
. . . . 96 . . .T . . C . . . . . . . . T . . T . 80 M60746 [20]
. . . . 88 . . .T . . G. . . . . . . .C . . A . 85 X83550 [18]
. . . . 76 . . .C . . T . . . . . . . . T . . T . 75 Z80785 [18]
. T . . 88 . . .C . . T . . . . . . . .T . . C . 70 Z80786 [18]
. . . . 84 . . .C . . A. . T . . T . .C . . C . 85 Z83735 [1]
. . . . 88 . . .C . . T . . . . . . . . T . . C . 70 X00090 [21]
. . . . 92 . . .C . . T . . . . . . . . T . . C . 70 M26150 [22]
Fig. 2. Alignment analysis of sequence of randomly selected sample no. 5191 amplimer revealing 100% homology between studied sequence and reference
sequence (GenBank accession no. Z83737).
J. Orchel et al. / Biochimica et Biophysica Acta 1689 (2004) 42–4644binding was visualized by the avidin–biotin complex
(ABC) technique with Novostain Super ABC Kit (NCL-
ABCu, Novocastra, UK), and using diaminobenzidine as
chromogen. The sections were counterstained with Mayer’s
hematoxylin solution. Fields showing the highest density of
positive cells were evaluated by light microscope. One
thousand tumor cells were counted in each specimen and
the percentage of immunopositive cells (labeling index) was
assessed.
2.5. Statistical analysis
The association of H3 mRNA expression, Ki-67 LI,
tumor grade and survival time was evaluated by Spearman’s
rank correlation coefficients. The mean values in grades II–
IV were compared by Mann–Whitney U-test. For multivar-
iate survival analysis patient age, gender, tumor grade, Ki-67
LI and H3 mRNA levels were entered into Cox’s regression
analysis. The level of significance was set to P<0.05.3. Results
3.1. Homology of H3 mRNA isoforms
Comparison of H3j mRNA with other replication-de-
pendent H3 mRNA sequences revealed homology of 82–
85%. Primers and probes specific for H3j are complemen-
tary to other H3 mRNA isoforms in 80–95% for forward
primer, 70–85% for reverse primer and 76–96% for probe
(Table 1).Table 2
H3j mRNA levels and Ki-67 labeling indices (in %) in 30 brain
astrocytomas grades II– IV
H3j mRNA copy number103
(meanFS.D., range)
Ki-67 labeling index
(meanFS.D., range)
G II 2.99F1.12 (1.10–4.90) 3.1F0.8 (1.8–4.1)
G III 5.31F4.93 (0.60–18.83) 9.1F3.1 (4.8–13.8)
G IV 9.97F5.86 (1.45–21.18) 14.2F4.9 (7.8–22.5)
Abbreviations: S.D., standard deviation.3.2. Sequence analysis of amplification product
Because the primers and probe used in our study are in
great measure complementary to all replication-dependent
histone mRNA isoforms, we performed sequencing of the
amplimer product. The amplimer sequence was then com-
pared with the reference sequence GenBank accession no.
Z83737. The analysis confirmed specific amplification of
H3j isoform (Fig. 2).
3.3. H3 mRNA level and Ki-67 labeling index
The mean H3 mRNA and Ki-67 index values in astro-
cytomas grade II– IV are summarized in Table 2. An
association of H3 mRNA level with tumor grade (R=0.56,
P=0.0012) and Ki-67 index (R=0.58, P=0.0008) was found.
The mean level of H3 mRNA in high-grade tumors (grade
III and IV) was near 2.5-fold higher than in low-grade
tumors (grade II) (7.4103F5.8103 vs. 3.0103F
1.1103), Table 2, Fig. 3. The difference of mean H3
mRNA level in low-grade and high-grade astrocytomas
was statistically significant (P=0.0028), discriminating
these tumors at the confidence interval of 95%. The H3Fig. 3. H3j mRNA levels in 30 brain astrocytomas grades II– IV. The
expression of H3 correlates with tumor grade and increases with
malignancy.
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patient survival time (R=0.50, P=0.005 vs. R=0.46,
P=0.0097); however, at multivariate analysis only the pa-
tient age proved to be predictive of patient survival
(P=0.0003, Cox’s proportional hazard model).4. Discussion
A significant diversity of sequence of histone H3 genes
and mRNAs and the highly conserved nature of histone
proteins results from the coding of a given amino acid by
different triplets (codon degeneracy) [23]. Because two
subtypes of replication-dependent H3 protein (H3.1 and
H3.2) are encoded by a plethora of 11 isoforms of the H3
gene and mRNA, the comprehensive quantitation of H3
expression meets some difficulties. The design of consensus
primers is hindered by the fact that it is impossible to define
a domain homologous in 100% to all the isoforms. Al-
though designed primers and probe are in great measure
complementary to other H3 mRNA isoforms, the sequenc-
ing of PCR product confirmed specific amplification of the
reference sequence (Fig. 2). This is probably caused by an
absolute matching of 3V ends of primers and H3j mRNA
isoform. On the other hand, single base mismatches, result-
ing from the degeneracy at the 3V end of the primers in
relation to other mRNA isoforms might have obviated
extension of primers [23,24].
An amplification of all 11 mRNA isoforms with separate
pairs of primers in consecutive wells is possible; however,
this would obviously be a time-consuming and more ex-
pensive procedure. An attempt to amplify all isoforms in a
single well using multiple primer pairs (multiplex PCR)
could lead to primer complementarity (favoured by high
homology of primers, as stated above) and a formation of
primer–dimers [25,26]. Alternatively, primers and probes
containing multiple degenerate bases can be designed [23].
However, this approach frequently gives rise to nonspecific
PCR products [24]. Nucleotides in degenerate primers can
be replaced with modified bases or deoxyinosine; however,
melting temperature >70 jC is then required [23]. A large
number of A–T pairs in all H3 mRNA isoforms implies low
melting temperature, which substantially hinders the design-
ing of PCR reaction with the high annealing temperature
required for specificity.
We decided to validate usefulness of quantitating H3
mRNA in brain astrocytomas. Analysis of our 30 cases
suggests that the level of H3 mRNA is a useful biomarker of
malignancy and proliferative activity in brain astrocytomas.
Additionally, H3 mRNA level, assessed quantitatively by
QRT-PCR technique may serve as an adjunct prognostic
factor in these tumors.
Using an ISH technique, Rautiainen et al. [27] found an
association between histone mRNA and Ki-67 labeling
indices of R=0.44. Furthermore, histone mRNA expression
proved to be an independent prognostic factor. However, inthis semi-quantitative study the oligonucleotide cocktail,
detecting H2B, H3 and H4 mRNA was used.
Replication-dependent histone genes are coordinately
expressed during the S-phase of the cell cycle [28,29].
Presumably, the expression of a single isoform is represen-
tative for the whole subtype of histone genes (e.g. H3 or
H4); however, this assumption requires comprehensive
validation.
Reviewing the literature, we did not find any study using
a pair of primers complementary to mRNA of all isoforms
of any histone gene. In papers on H3 expression, no data
regarding specificity of the probes in relation to H3 mRNA
isoform are provided [2,5,27,30–33]. Sequence analysis of
primers used in studies on H4 mRNA [34,35] in fact reveals
that a single H4 mRNA isoform was quantitated in these
experiments. The histone H4 gene, like its H3 core coun-
terpart, has multiple isoforms and related mRNAs.
In summary, our observations support the usefulness of
histone H3 mRNA study in assessing proliferative activity
and progression in brain gliomas. The applicability of
primers and probe labeled with FAM and TAMRA, detect-
ing a single H3 mRNA isoform was validated earlier in
other neoplastic tissues [8–11].Acknowledgements
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